TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12582815

Group type: EXPERIMENTAL
Intervention: 4-h mixed AA co-infusion (120 g mixed AA: 26.4 g l-lysine + l-arginine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10-h mixed AA co-infusion (240 g mixed AA: 52.8 g l-lysine + l-arginine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4-h Lys-Arg co-infusion (25 g each)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4-h mixed AA co-infusion
Number of subjects: 24
Study: 10587340

Group type: EXPERIMENTAL
Intervention: Intraoperative aprotinin
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study: 10163573

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50 micrograms twice daily via Diskhaler
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sodium cromoglycate 20mg 4 times daily via spin operated dry powder inhaler
Number of subjects: 225
Study: 1833610

Group type: EXPERIMENTAL
Intervention: Oestradiol gel applied once/day on 800 cm2 of skin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oestradiol patch applied for 3-5 days on 20 cm2 of skin
Number of subjects: 0
Study: 6129673

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Favorable events
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Unfavorable events
Number of subjects: 410
Study: 6231043

Group type: EXPERIMENTAL
Intervention: 4% lignocaine spray 2 ml
Number of subjects: 48

Group type: COMPARATOR
Intervention: Halothane (0.5 or 1.5%) and thiopentone (4.5 or 10 mg kg‐1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thiopentone (higher dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thiopentone (increased dose)
Number of subjects: 48
Study: 31629326

Group type: EXPERIMENTAL
Intervention: FIFA 11+ program performed 3 times per week for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular warm-up program (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FIFA 11+ program
Number of subjects: 24
Study: 29772114

Group type: EXPERIMENTAL
Intervention: Intravesical instillation with highly concentrated hyaluronic acid/chondroitin sulphate (HA/CS)
Number of subjects: 92
Study: 27079247

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Routinely used chlorhexidine gluconate solutions
Number of subjects: 105
Study: 24048369

Group type: EXPERIMENTAL
Intervention: Combined prednisolone (20 mg/day) and LMW heparin (1 mg/kg/day) starting on the first day of ovarian stimulation and one day after oocyte retrieval, respectively.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 334
Study: 23622992

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail Antirotation (PFNA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Gamma3 nail
Number of subjects: 61
Study: 20307323

Group type: EXPERIMENTAL
Intervention: Walking training at anaerobic threshold
Number of subjects: 60
Study: 18705820

Group type: EXPERIMENTAL
Intervention: 10 mg/day naloxone PR
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 20 mg/day naloxone PR
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 40 mg/day naloxone PR
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 2:1 dose ratio of oxycodone to naloxone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 15925083

Group type: EXPERIMENTAL
Intervention: emergency extracorporeal shock wave lithotripsy (eESWL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: medical therapy alone
Number of subjects: 100
Study: 12661534

Group type: EXPERIMENTAL
Intervention: Intensive counseling consisting of three 1-hour sessions
Number of subjects: 581

Group type: COMPARATOR
Intervention: Routine counseling
Number of subjects: 581
Study: 10857770

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (10000 U/kg body weight)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (1000 U/kg body weight)
Number of subjects: 18
Study: 8642156

Group type: EXPERIMENTAL
Intervention: Competency Clinic assessment by a specially trained nurse in collaboration with a multidisciplinary team
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Geriatrician assessment using a decisional aid
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Generic Instrument designed for any advance directive
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Specific Instrument designed for the 'Let Me Decide' advance directive
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Standardized Mini‐Mental Status Examination (SMMSE)
Number of subjects: 96
Study: 1499598

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 mg non-fasting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moxonidine 0.2 mg fasting
Number of subjects: 18
Study: 6670341

Group type: EXPERIMENTAL
Intervention: Regular, non medicamentous individual treatment in group A
Number of subjects: 141

Group type: COMPARATOR
Intervention: Unique recommendation concerning preventive measures in group B
Number of subjects: 141
Study: 31689832

Group type: EXPERIMENTAL
Intervention: Taoren Honghua Jian granule (THJG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29204689

Group type: EXPERIMENTAL
Intervention: Adhesive patching
Number of subjects: 107

Group type: COMPARATOR
Intervention: Over-glasses patching
Number of subjects: 107
Study: 27484299

Group type: EXPERIMENTAL
Intervention: Short-stay group (2 months inpatient + biweekly visits for 4 months)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Long-stay group (6 months inpatient + 6 monthly return visits)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Short-stay group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Long-stay group
Number of subjects: 80
Study: 24766757

Group type: EXPERIMENTAL
Intervention: Project SHARE intervention (n = 546 patients)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Usual care (n = 640 patients)
Number of subjects: 1186
Study: 21226769

Group type: EXPERIMENTAL
Intervention: Heat-treated Jatropha platyphylla kernel meal (H-JPKM) diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Soybean meal (SBM) diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fish meal (FM) diet (Control)
Number of subjects: 15
Study: 20681279

Group type: EXPERIMENTAL
Intervention: Modified Tianxiong Powder (MTP) for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wuzi Yanzong Pill (WYP) for 3 months
Number of subjects: 80
Study: 17960809

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Unblinded studies
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: General public perspective
Number of subjects: 288
Study: 16208802

Group type: EXPERIMENTAL
Intervention: PC 7000/EB‐Prophy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PC 7000/EB17
Number of subjects: 90

Group type: COMPARATOR
Intervention: SE
Number of subjects: 90
Study: 11781402

Group type: EXPERIMENTAL
Intervention: Valacyclovir (1 gram, three times daily for 24 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Valacyclovir (in patients with high levels of disease activity)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (in patients with high levels of disease activity)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 70
Study: 10522614

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant interferon-beta
Number of subjects: 200

Group type: COMPARATOR
Intervention: Interferon-alpha-2b and ribavirin (combination therapy)
Number of subjects: 200
Study: 8540716

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily) plus rifampin (900 mg/day, single morning dose for 45 days)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily) plus streptomycin (1 g/day, intramuscularly for 14 days)
Number of subjects: 194
Study: 1771284

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin 2 micrograms/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no nitroglycerin)
Number of subjects: 30
Study: 6167119

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 65

Group type: COMPARATOR
Intervention: Tetracycline chloride 1 g/day for one week
Number of subjects: 65
Study: 30932750

Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplement
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL) supplement
Number of subjects: 12
Study: 31801326

Group type: EXPERIMENTAL
Intervention: Diabetes specific nutrition supplement (DSNS) along with lifestyle intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 120
Study: 27082845

Group type: EXPERIMENTAL
Intervention: Rinsing with water before toothbrushing
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rinsing with water after toothbrushing
Number of subjects: 48
Study: 25792132

Group type: EXPERIMENTAL
Intervention: Children alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children with bystanders present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children with bystanders behind a barrier
Number of subjects: 0
Study: 23630119

Group type: EXPERIMENTAL
Intervention: l-dopa/carbidopa/entacapone (LCE)
Number of subjects: 745

Group type: COMPARATOR
Intervention: l-dopa/carbidopa (LC)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: l-dopa dose
Number of subjects: 745
Study: 21296600

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (GTN)
Number of subjects: 153
Study: 19062112

Group type: COMPARATOR
Intervention: Low Sodium Intake (LSI) - matched placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal Sodium Intake (NSI) - 80 mmol/day of oral sodium supplements
Number of subjects: 0
Study: 16443859

Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 16 mg candesartan
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate and 16 mg candesartan (combined therapy)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15545863

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study: 10904464

Group type: EXPERIMENTAL
Intervention: Preoperative dalteparin sodium (subcutaneous, once daily)
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: Postoperative dalteparin sodium (subcutaneous, once daily)
Number of subjects: 1472

Group type: COMPARATOR
Intervention: Warfarin sodium (postoperative)
Number of subjects: 1472
Study: 9068505

Group type: EXPERIMENTAL
Intervention: Acute catheterization
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Rescue angioplasty
Number of subjects: 296

Group type: COMPARATOR
Intervention: Thrombolytic regimen (alteplase, urokinase, or both)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Catheterization strategy (acute vs deferred)
Number of subjects: 296
Study: 8378155

Group type: EXPERIMENTAL
Intervention: Oral ketamine at a dose of 6 mg/kg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Oral meperidine/promethazine combination at doses of 2 mg/kg and 0.5 mg/kg respectively
Number of subjects: 2
Study: 3752621

Group type: EXPERIMENTAL
Intervention: Prick test with extracts of larval and adult midges
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Radioallergosorbent test (RAST) with extracts of larval and adult midges
Number of subjects: 303

Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 303
Study: 30891524

Group type: EXPERIMENTAL
Intervention: Hydroimplantation (group H)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Viscoimplantation (group V)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups (H and V)
Number of subjects: 84
Study: 26771908

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) and aspirin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 32
Study: 25574801

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Moderate Sedation (MS)
Number of subjects: 149
Study: 23786503

Group type: EXPERIMENTAL
Intervention: Topical 4% nicotinamide
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1% clindamycin
Number of subjects: 80
Study: 21955937

Group type: EXPERIMENTAL
Intervention: 500 mg extended-release niacin for 4 weeks, then 1000 mg extended-release niacin for 4 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 19000717

Group type: EXPERIMENTAL
Intervention: Hypoxic condition (12.7 kPa PIO(2))
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normoxic condition (21 kPa PIO(2))
Number of subjects: 21
Study: 16923416

Group type: EXPERIMENTAL
Intervention: Zofenopril (n = 253)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo (n = 273)
Number of subjects: 526
Study: 15570149

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 41
Study: 11346394

Group type: EXPERIMENTAL
Intervention: Enucleation preceded by external beam radiotherapy
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Enucleation only
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1003
Study: 9214419

Group type: EXPERIMENTAL
Intervention: Core set of outcome variables for assessment of JA
Number of subjects: 0
Study: 7641719

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 4% lignocaine
Number of subjects: 0
Study: 2568812

Group type: EXPERIMENTAL
Intervention: Iosimide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 100
Study: 361645

Group type: EXPERIMENTAL
Intervention: Mediastinoscopy (Group A)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Thoracotomy (Group B)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Overall survival (Group B)
Number of subjects: 130
Study: 31226187

Group type: EXPERIMENTAL
Intervention: Computer-assisted implant planning and template-guided implant placement (CAIPP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional protocols (control)
Number of subjects: 73
Study: 29121061

Group type: EXPERIMENTAL
Intervention: Tafenoquine 400 mg once daily for 3 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chloroquine 2500 mg total dose (1500 mg chloroquine base) over 3 days plus primaquine 15 mg daily for 14 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chloroquine/primaquine
Number of subjects: 70
Study: 26674119

Group type: EXPERIMENTAL
Intervention: Pulvers' figure rating scale
Number of subjects: 147
Study: 25803763

Group type: EXPERIMENTAL
Intervention: Medication therapy management reconciliation service (MRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (non-MRS)
Number of subjects: 0
Study: 22517293

Group type: EXPERIMENTAL
Intervention: L-arginine (5 g/day) and HDEL
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/day) and HDEL
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: L-arginine, selenium and HDEL
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: HDEL
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control diet (HDEL)
Number of subjects: 84
Study: 20683147

Group type: EXPERIMENTAL
Intervention: Elevated CRP (top 15 percentile; CRP >= 2.09 mg/L)
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Urban region participants
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 3133
Study: 19000538

Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no azelnidipine)
Number of subjects: 45
Study: 16838827

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg to 40 mg daily plus IPT 1 session weekly
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg to 40 mg daily
Number of subjects: 39
Study: 12636462

Group type: COMPARATOR
Intervention: Usual care (n = 271)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Exercise alone (n = 269)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus exercise (n = 266)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) alone (n = 286)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: CBT (n = 552)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Exercise (n = 531)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Exercise alone or in combination with CBT
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: CBT alone
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Neither treatment
Number of subjects: 1092
Study: 11028140

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 0
Study: 9437561

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing rod (LNG rod)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Norplant capsule implants
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study: 8217759

Group type: EXPERIMENTAL
Intervention: Naftifine (Exoderil) applied twice daily for 4 weeks
Number of subjects: 269

Group type: COMPARATOR
Intervention: 1% clotrimazole plus 1% hydrocortisone (CHC; Canesten HC) applied twice daily for 4 weeks
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Naftifine (Exoderil)
Number of subjects: 269

Group type: COMPARATOR
Intervention: 1% clotrimazole plus 1% hydrocortisone (CHC; Canesten HC)
Number of subjects: 269
Study: 3330524

Group type: EXPERIMENTAL
Intervention: Alinidine (40 mg three times a day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol and atropine (0.2 mg kg‐1 and 0.04 mg kg‐1 respectively)
Number of subjects: 18
Study: 31996370

Group type: EXPERIMENTAL
Intervention: PSA ≤ 1 ng/mL
Number of subjects: 33897

Group type: EXPERIMENTAL
Intervention: PSA 1.01-2.5 ng/mL
Number of subjects: 33897

Group type: EXPERIMENTAL
Intervention: PSA ≤ 0.5 ng/mL, aged ≥65 years
Number of subjects: 33897

Group type: EXPERIMENTAL
Intervention: PSA ≤ 1 ng/mL, black men
Number of subjects: 33897
Study: 29660421

Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certolizumab 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26718934

Group type: EXPERIMENTAL
Intervention: Ammonia inhalation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no ammonia inhalation)
Number of subjects: 15
Study: 25037182

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-PRF (control)
Number of subjects: 78
Study: 22290884

Group type: EXPERIMENTAL
Intervention: RV-PA conduit placement on the left side to the neo-aorta
Number of subjects: 60

Group type: COMPARATOR
Intervention: RV-PA conduit placement on the right side to the neo-aorta
Number of subjects: 60
Study: 20178050

Group type: EXPERIMENTAL
Intervention: RVX-208
Number of subjects: 0
Study: 17689192

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (simple relaxation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hypnosis (highly hypnotic susceptible patients)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hypnosis (less susceptible patients)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 15671361

Group type: EXPERIMENTAL
Intervention: Listening to a relaxation audiotape before and during mammography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Listening to a music audiotape before and during mammography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no audiotape)
Number of subjects: 0
Study: 12500001

Group type: EXPERIMENTAL
Intervention: Pediatric Crohn's Disease Activity Index (PCDAI) in clinical practice setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pediatric Crohn's Disease Activity Index (PCDAI) in randomized controlled trial (RCT) setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in PCDAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in PCDAI in RCT setting
Number of subjects: 0
Study: 11172797

Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg) and Ethinylestradiol (0.03 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (0.125 mg) and Ethinylestradiol (0.03 mg)
Number of subjects: 18
Study: 8927471

Group type: EXPERIMENTAL
Intervention: Chlorambucil (n=19)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (n=13)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Chlorambucil (n=26)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cyclophosphamide (n=17)
Number of subjects: 75
Study: 7971012

Group type: EXPERIMENTAL
Intervention: PCAT program
Number of subjects: 88

Group type: COMPARATOR
Intervention: At-risk control group
Number of subjects: 88
Study: 2893635

Group type: EXPERIMENTAL
Intervention: Koe 3290 100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Koe 3290
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atenolol 25, 50 and 100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Koe 3290 12.5, 25, 50 and 100 mg
Number of subjects: 14
Study: 29325922

Group type: EXPERIMENTAL
Intervention: PARO (individual, nonfacilitated 15-minute sessions, 3 afternoons per week for 10 weeks)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Plush toy (as per PARO but with artificial intelligence disabled)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415